|
FORM 10-Q
EXHIBIT 11-1
<PAGE>
EXHIBIT 11.1
BIOPSYS MEDICAL, INC.
STATEMENT RE: COMPUTATION OF NET INCOME (LOSS) PER SHARE
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
March 31, March 31,
-------------------------- ----------------------------
1997 1996 1997 1996
---------- ----------- ---------- -------------
<S> <C> <C> <C> <C>
Net income (loss) $ 601,000 $(1,031,000) $ 607,000 $ (2,545,000)
---------- ----------- ---------- -------------
---------- ----------- ---------- -------------
Shares used in computing net income (loss)
per share:
Weighted average common shares outstanding
during the period 9,856,000 1,833,218 9,794,000 1,811,218
Equivalent shares representing shares
issuable upon conversion of preferred
stock and preferred warrants:
Series A - 833,333 - 833,333
Series B - 1,333,333 - 1,333,333
Series C - 3,051,590 - 3,051,590
Series C warrants - 32,624 - 32,624
Equivalent shares representing shares
issuable upon conversion of common
stock options 1,361,000 556,902 1,237,000 556,902
---------- ----------- ---------- -------------
Total shares used in computing historical
net income (loss) per share 11,217,000 7,641,000 11,031,000 7,619,000
---------- ----------- ---------- -------------
---------- ----------- ---------- -------------
Net income (loss) per share $ 0.05 $ (0.13) $ 0.06 $ (0.33)
---------- ----------- ---------- -------------
---------- ----------- ---------- -------------
</TABLE>
FINANCIAL DATA SCHEDULE
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED BALANCE SHEET AND STATEMENT OF OPERATIONS CONTAINED IN THE BIOPSYS
MEDICAL, INC. FORM 10Q FOR THE NINE MONTHS ENDED MARCH 31, 1997 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-START> JUL-01-1996
<PERIOD-END> MAR-31-1997
<CASH> 6,538,000
<SECURITIES> 15,222,000
<RECEIVABLES> 2,538,000
<ALLOWANCES> (146,000)
<INVENTORY> 2,602,000
<CURRENT-ASSETS> 27,416,000
<PP&E> 1,692,000
<DEPRECIATION> (302,000)
<TOTAL-ASSETS> 42,289,000
<CURRENT-LIABILITIES> 2,033,000
<BONDS> 0
<PREFERRED-MANDATORY> 0
<PREFERRED> 0
<COMMON> 10,000
<OTHER-SE> 40,246,000
<TOTAL-LIABILITY-AND-EQUITY> 42,289,000
<SALES> 10,045,000
<TOTAL-REVENUES> 10,045,000
<CGS> 4,236,000
<TOTAL-COSTS> 4,236,000
<OTHER-EXPENSES> 6,635,000
<LOSS-PROVISION> 80,000
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 607,000
<INCOME-TAX> 0
<INCOME-CONTINUING> 607,000
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 607,000
<EPS-PRIMARY> .06
<EPS-DILUTED> .06
</TABLE>
|
